An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
ADOCIA Announces the Release of its Universal Registration Document for the Year 2022
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
LYON, France--(BUSINESS WIRE)--
Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the filing of its 2022 Universal Registration Document with the “Autorité des marchés financiers” (AMF - the French financial markets regulator) on April 26, 2023.
An electronic copy of this document is available on the company’s website (www.adocia.com) as well as on the website of the AMF. Hard copies are available upon request at the company’s headquarters located 115, avenue Lacassagne, 69003 Lyon.
The Universal Registration Document includes the 2022 annual financial report, which includes the 2022 Management Report and the corporate governance report.
About Adocia
Adocia is a biotechnology Company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The Company has a broad portfolio of drug candidates based on four proprietary technology platforms:
1) The BioChaperone® technology for the development of new generation insulins and products combining insulins with other classes of hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with a first application in pancreatic cells transplantation; 4) AdoGel®, a long-acting drug delivery platform.
Adocia holds more than 25 patent families.
Based in Lyon, the Company has about 100 employees. Adocia is listed on the regulated market of EuronextTMParis (Euronext: ADOC; ISIN: FR0011184241).
Disclaimer
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those which are set forth in the “Risk Factors” section of the universal registration document that was filed with the French Autorité des marchés financiers on April 26, 2023 (a copy of which is available at www.adocia.com), in particular uncertainties that are linked to research and development, future clinical data, analyses, and the evolution of the economic context, the financial markets and the markets in which Adocia operates.
The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia as of this day. The occurrence of all or part of such risks could cause that actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.
This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia’s shares in any jurisdiction.
Adocia Press and Investors Relations
Ulysse Communication
Pierre-Louis Germain Margaux Puech Pays d’Alissac
Bruno Arabian +33 (0)6 64 79 97 51
adocia@ulysse-communication.com
